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Objective: There is an increasing need for vascular grafts in the field of surgical revascularization. However, smaller
vascular grafts made from synthetic biomaterials, particularly those <5 mm in diameter, are associated with a high
incidence of thrombosis. Fibroin is a biodegradable protein derived from silk. Silk fibroin from Bombyx mori provides an
antithrombotic surface and serves as a scaffold for various cell types in tissue engineering. We evaluated the potential of
fibroin to generate a vascular prosthesis for small arteries.
Methods:A small vessel with three layers was woven from silk fibroin thread. These fibroin-based grafts (1.5 mm diameter,
10 mm length) were implanted into the abdominal aorta of 10- to 14-week-old male Sprague-Dawley rats by end-to-end
anastomosis. Polytetrafluoroethylene (PTFE)-based grafts were used as the control. To investigate the origin of the cells
in the neointima and media, bone marrow transplantation was performed from green fluorescent protein (GFP) rats to
wild-type rats.
Results: The patency of fibroin grafts at 1 year after implantation was significantly higher than that of PTFE grafts (85.1% vs
30%, P< .01). Endothelial cells and smooth muscle cells (SMCs) migrated into the fibroin graft early after implantation and
became organized into endothelial and medial layers, as determined by anti-CD31 and anti--smooth muscle actin immuno-
staining.The total number of SMCs increased1.6-fold from1month to3months.Vasa vasorumalso formed in the adventitia.
Sirius red staining of the fibroin grafts revealed that the content of collagen significantly increased at 1 year after implantation,
with a decrease in fibroin content. GFP-positive cells contributed to organization of a smooth muscle layer.
Conclusions: Small-diameter fibroin-based vascular grafts have excellent long-term patency. Bone marrow-derived cells
contribute to vascular remodeling after graft implantation. Fibroin might be a promising material to engineer vascular
prostheses for small arteries. ( J Vasc Surg 2010;51:155-64.)
Clinical Relevance: The present study evaluated the efficacy of a fibroin, a new silk-based biodegradable material, to
generate small diameter grafts. When implanted in rat abdominal aorta, a fibroin-based graft (1.5 mm in diameter)
showed excellent long-term patency, with optimal mechanical properties. Endothelial cells and smooth muscle cells
migrated into the fibroin graft early after implantation and became organized into endothelial and medial layers,
generating a vascular-like structure. Our findings suggest that a silk fibroin might be a promising material to develop
vascular prostheses for smaller arteries.Small-diameter prostheses are needed for peripheral
revascularization procedures.1 Autologous saphenous vein
is considered the material of choice for bypass grafts to
relieve symptoms or avoid amputation in patients with
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fluoroethylene (ePTFE) and polyethylene terephthalate
(Dacron), particularly those 5 mm in internal diameter,
are associated with a high incidence of thrombosis, espe-
cially when the distal anastomosis is below the knee.3
To overcome these limitations, various tissue-
engineered vascular grafts have been developed.4 The util-
ity and clinical experience of these new grafts have been
reported.5-9 The most promising approach was described
by L’Heureux et al,7,8 who developed a completely autol-
ogous technique called sheet-based tissue engineering.
Autologous tissue-engineered vascular grafts have been im-
planted as arteriovenous shunts in 10 patients with end-
stage renal disease. In five patients, the grafts were func-
tioning for hemodialysis at 6 to 20 months after
implantation.9 Despite these encouraging initial results,
this method takes a long time, about 24 days, and thus
cannot be applied for emergency surgery.
Silk has been used in biomedical applications for cen-
turies, primarily for suturing. Silk fibers are composed
primarily of two types of proteins: (1) sericin, the antigenic
gum-like protein surrounding the fibers, and (2) fibroin,
the core filaments of silk consisting of highly organized
-sheet crystal regions and semicrystalline regions respon-
sible for silk’s elasticity compared with fibers of similar
tensile integrity.10 If sericin is removed, the biologic re-
sponses to the core fibroin fibers appear to be comparable
with the responses to most other commonly used biomate-
rials. Furthermore, silk is susceptible to proteolytic degra-
dation in vivo and is absorbed slowly.11-14
Fibroin provides an antithrombotic surface and serves
as a scaffold for various cell types in tissue engineering. Silk
fibroin offers versatility in matrix scaffold design for engi-
neering of a variety of tissues in which mechanical perfor-
mance and biologic interactions are required, such as bone,
ligaments, tendons, blood vessels, and cartilage.15-18
In the present study, we created a small-diameter bio-
degradable fibroin-based graft with optimal mechanical
properties and evaluated its in vivo patency, cellularization,
and degradation in the rat arterial circulation for up to 18
months. We also examined the participation of bone mar-
row (BM)-derived cells in the formation of a vascular-like
structure in the implanted prosthesis. Our findings suggest
that silk fibroin might be a promising material to develop
vascular prostheses for smaller arteries.
MATERIALS AND METHODS
Fabrication of silk fibroin vascular graft. Artificial
blood vessels were made by a combination of plaiting of silk
fibers and winding of cocoon filaments on a round sectional
core, which was a vinyl chloride rod. To produce artificial
blood vessels by this method, 36 thin silk threads (14
denier/thread) were first plaited together. After that, three
or four cocoon filaments (1.6 to 1.8 denier/filament) were
reeled around the plaited silk fibers. The combination of
plaiting of silk fibers and winding of cocoon filaments was
performed two or more times.A degumming process was used to remove the water-
soluble sericin component. The tube was dipped in a fi-
broin solution to make the fibroin filaments stick together,
dried, and fixed in ethanol, and the cocoon filament vessel
was removed from the central core. This material was left
under heat (80°C) in water so that the cocoon filament
vessel could be easily separated from the central core. Thus,
an artificial blood tube with a 1.5-mm inner diameter made
from cocoon filaments was produced.
Animals. Male Sprague-Dawley (SD) rats weighing
400 to 500 g were purchased from SLC (Shizuoka, Japan).
Transgenic rats (SD background) that ubiquitously express
enhanced green fluorescent protein (GFP) were donated by
Dr Masaru Okabe (Osaka University, Osaka, Japan).19 All
rats were kept in microisolator cages with a 12-hour light/
dark cycle. All experimental procedures and protocols were
approved by the Animal Care and Use Committee of the
University of Tokyo and complied with the Guide for the
Care and Use of Laboratory Animals (National Institutes of
Health publication No. 86-23, revised 1985).
Surgical procedure. A silk fibroin graft (10 mm long,
1.5 mm inner diameter) was implanted into the rat abdom-
inal aorta, which had a diameter of about 1.5 mm. Rats
were anesthetized with an intraperitoneal injection of pen-
tobarbital (50 mg/kg body weight). The abdominal aorta
was exposed and the aortic branches in this segment were
ligated.
After an intravenous injection of heparin (100 IU/kg),
the proximal and distal portions of the infrarenal aorta were
clamped. A 10-mm segment of aorta was removed and
replaced by a fibroin graft by end-to-end anastomosis using
interrupted 9-0 monofilament nylon sutures (BEAR, Ja-
pan), starting with two stay sutures at 180° to each other,
then suturing the front wall, followed by the back wall.
Each anastomosis required 10 to 12 stitches. The distal,
then the proximal vascular clamps were slowly removed,
and flow was restored through the fibroin graft. Total
ischemia time was 30 to 60 minutes.
A small tube made of polytetrafluoroethylene (PTFE),
1.5 mm in diameter (HAGITEC, Chiba, Japan), was im-
planted into the rat abdominal aorta in the same manner.
Graft patency was confirmed visually. No anticoagu-
lants or antiplatelet agents were administered postopera-
tively. Two animals died from surgical complications, such
as bleeding from the site of anastomosis, and were not
included in this study.
Graft patency was monitored by color Doppler imaging
and pulse waves recorded with a 12-MHz sector probe and
an echo-imaging apparatus (EnVisor M2540A, Phillips,
Tokyo) at 2, 4, 8, 12, 24, 48, and 72 weeks, under
anesthesia with pentobarbital. Graft diameter and blood
flow velocity were measured. Signs of thrombosis and
aneurysm formation were carefully checked. Angiography
was performed before sacrifice by injection of 1mL contrast
material (Hexabrix 320, Guerbet, France), and blood flow
was assessed using a C-arm digital fluoroscopy system (Si-
rus Power/C, Hitachi Medico, Tokyo, Japan).
JOURNAL OF VASCULAR SURGERY
Volume 51, Number 1 Enomoto et al 157Histologic examination. Three to five animals were
killed with an overdose of pentobarbital at 2, 4, 12, 24, 48,
and 72 weeks. Before euthanasia, rats underwent a general
physical examination to evaluate their condition. At death,
the rats were perfused with 0.9% saline solution through
the left ventricle.
The grafts were carefully removed with surrounding
tissue, cut transversely in the midline into two pieces,
and fixed in methanol or snap-frozen in OCT compound
(Tissue-Tek, Tokyo) for histologic analyses. Methanol-
fixed samples were embedded in paraffin. Paraffin-
embedded sections (4-m thick) were processed for
hematoxylin and eosin staining.
Immunohistochemical staining was performed as
previously reported.20 The sections were incubated with
primary antibodies, including alkaline phosphatase-
conjugated anti--smooth muscle actin (SMA; clone 1A4,
Sigma-Aldrich, St. Louis, Mo), anti-rat CD31 (clone TLD-
3A12, BD Biosciences, San Jose, Calif), or anti-CD68
(clone ED1, Serotec, Oxford, United Kingdom), followed
by incubation with biotinylated anti-mouse immunoglob-
ulin (Ig) G secondary antibody (DAKO, Glostrup, Den-
mark) and subsequent use of the avidin-biotin complex
technique and Vector Red substrate (Vector Laboratories,
Burlingame, CA). Nuclei were counterstained with hema-
toxylin.
Sirius red polarization method for collagen
staining. Sirius red polarization microscopy was per-
formed, as described previously, to visualize interstitial
collagen and fibroin.21 Fresh frozen sections (5 m) were
rinsed with distilled water and incubated with 0.1% Sirius
red (Sigma-Aldrich) in saturated picric acid for 90 minutes.
Sections were rinsed twice with 0.03 N HCl for 1 minute
each time and then immersed in distilled water. After
dehydration with 70% ethanol for 30 seconds, the sections
were coverslipped. The stained sections were examined
under a polarization microscope (Eclipse LV100POL, Ni-
kon, Tokyo). Images were digitized with a CCD camera
(Digital Sight DS-2Mv, Nikon). As the fiber thickness
increases, the color changes from green to red.
BM transplantation. To keep track of bone marrow
(BM)-derived cells in the process of graft remodeling, we
performed BM transplantation (BMT) from GFP rats to
wild-type SD rats, as described previously.20,22 BM cells
were harvested from the femurs and tibias of GFP rats.
Eight-week-old male wild-type rats were lethally irradiated
with a total dose of 15 Gy (MBR-1520RB, Hitachi). One
day later, the recipient rats received unfractionated BM cells
(3 107) suspended in 1 mL phosphate-buffered saline by
tail vein injection. Peripheral leukocytes (80% to 90%) had
been reconstituted as determined by flow cytometry. We
confirmed 80% bone marrow chimerism.23 At 4 to 16
weeks after BMT, fibroin grafts were implanted into the
chimeric rats.
Cell culture. BMCs were harvested from the femurs
and tibias of donor rats as described previously.23 For BMC
seeding, fibroin sheets (1 1 cm) were placed in a 24-well
plate. Cells were seeded onto the fibroin sheets (5  106cells/well) by direct pipetting and incubated in 1 mL Dul-
becco modified Eagle medium supplemented with 10% fetal
bovine serum, 50 U/mL penicillin, and 50 g/mL strepto-
mycin at 37°C in 5% carbon dioxide for 7 days. The cell
culture medium was changed every 4 days. At 7 days, the
seeded fibroin sheets were gently washed in phosphate buff-
ered saline and fixed for scanning electron microscopic study.
Scanning electron microscopy. Samples were fixed
in 2% paraformaldehyde and 2.5% glutaraldehyde, and
then postfixed in 1% osmium tetroxide and dehydrated
in a graded series of ethanol. After critical point drying,
samples were sputter coated with a thin layer of platinum/
palladium and analyzed with a scanning electron micro-
scope (S-3500N, Hitachi, Tokyo).
Double-immunofluorescence study. Frozen sec-
tions were incubated with anti-GFP rabbit polyclonal anti-
body (Molecular Probes, A11122, Eugene, Ore) and a
cell-specific primary antibody (Cy3-conjugated anti-SMA
[Sigma-Aldrich], anti-rat CD31 [BD Biosciences], anti-
CD45 [clone sc-1178, Santa Cruz Biotechnology, Santa
Cruz, Calif] or biotinylated anti-SM1 antibody [clone
KM3669, Kyowa Hakko Kogyo, Tokyo]). Alexa Fluor
488-labeled anti-rabbit IgG antibody (Molecular Probes)
and Cy3-conjugated anti-mouse antibody (Jackson Im-
munoResearch, West Grove, Pa) or Cy3-conjugated
streptavidin (Jackson ImmunoResearch) were used to vi-
sualize the distribution of primary antibodies. Nuclei were
counterstained with Hoechst 33258 (Sigma-Aldrich). The
sections were observed under a confocal microscope
(FLUOVIEW FV300, Olympus, Tokyo).
Statistics. Data are presented as mean  standard
error of the mean. Comparisons of means were performed
by one-way analysis of variance, followed by the Sheffe post
hoc test. Graft patency for each group was determined by
Kaplan-Meier analysis. The log-rank test was used to test
for differences between the groups. Statistical significance
was defined as P  .05.
RESULTS
Small-diameter vascular graft made of silk fibroin
and its biocompatibility. A 1.5 mm-diameter vascular
graft was fabricated from fibroin fibers (Fig 1, A and B).
Bone marrow cells (BMCs) from SD rats were seeded and
cultivated on the graft. Scanning electron microscopy dem-
onstrated that BMCs attached, differentiated, and coated
the surface of the graft at 7 days (Fig 1,C andD). To assess
the efficacy of fibroin-based grafts in vivo, a 1.5-mm-
diameter vascular graft made of fibroin was implanted into
the infrarenal abdominal aorta of a SD rat by end-to-end
anastomosis (Fig 1, E and F). The patency of the graft was
examined by ultrasound Doppler flow studies every 2
weeks, which revealed a flow signal in the graft, without
aneurysmal dilation (Fig 1, G, upper panel). Pulsed-wave
Doppler ultrasound imaging confirmed blood flow
through the patent graft (Fig 1, G, lower panel). Angiogra-
phy showed no aneurysmal dilation (Fig. 1, H).
Histologic changes in implanted fibroin graft.
Histologic analysis showed cellular intimal thickening and
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(scale bar, 60 m). B, A small artificial vascular graft was made from fibroin fibers. C and D, Attachment and
differentiation of bonemarrow cells (BMCs) on fibroin graft. Rat BMCs were isolated as described previously. At 7 days
after seeding, BMCs had spread and grown on the fibroin graft, forming cell sheets with a possible extracellular matrix
(C, scale bar, 200 m;D, scale bar, 50 m). E, The fibroin-based graft (1.5 mm internal diameter) was implanted into
rat abdominal aorta by end-to-end anastomosis (F). The arrows indicate anastomosis sites. Scale, 1mm.Ao,Aorta; IVC,
inferior vena cava.G, Blood flow within the graft was monitored by (upper panel) color Doppler imaging and (lower
panel) pulse wave velocity measurement. H, Angiography revealed a patent fibroin graft. The arrows indicate
anastomotic sites. G, Graft; V, inferior vena cava.
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formed along the fibroin graft at 2 weeks (Fig 2, B). The
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ks after implantation. The arrowheads indicate CD31-
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and extracellular matrix deposition of the fibroin graft.
Polarization microscopy showed that the content of fibroin
was decreased at 48 weeks after implantation (32.9% 
1.9%, P .05 vs 2 weeks; Fig 2,C). On the other hand, the
collagen content was markedly increased at 12 weeks
(544.9%  104.2%, P  .05 vs 2 weeks) and 48 weeks.
Histologic analysis showed no aneurysmal dilatation at any
time point (Fig 2, D). The graft diameter remained un-
changed up to 1 year after implantation. The grafts were
patent without luminal narrowing.
Excellent long-term patency of fibroin graft. The
patency of the 27 fibroin grafts and the 10 PTFE grafts
were compared (Fig 3,A). Four of the 10 PTFE grafts were
occluded 4 weeks, and one graft was occluded at 12
weeks. In contrast, only three of 27 fibroin grafts became
occluded. The overall 1-year patency of fibroin grafts was
85.0%, which was significantly higher than that of PTFE
grafts. Histologic analysis revealed that cells migrated to
the fibroin grafts and covered the luminal side completely
(Fig 3, B); however, no cell attachment occurred on PTFE
grafts (Fig 3,C). Thrombus formation was observed within
the occluded PTFE grafts.
Organization of vessel-like structure at 1 year after
fibroin graft implantation. Macroscopic observation of
the implanted fibroin graft at 1 year confirmed a smooth
luminal surface with no signs of thrombus or aneurysmal
dilatation (Fig 4, A). Histologic analysis of the fibroin
grafts showed formation of an endothelial layer and a
media-like smooth muscle layer (Fig 4, B). Vasa vasorum
had also formed in the adventitia. Anti-CD68 immuno-
staining revealed substantial infiltration of macrophages
and phagocytic phenomena around the remnants of fi-
broin. These findings indicate that organization of a vessel-
like structure could occur at 1 year using a fibroin graft as a
scaffold.
Origin of endothelial cells and SMCs that accumu-
lated along the graft. Fibroin grafts were implanted in the
BMT rats whose BM cells had been reconstituted by those
from GFP rats. At 12 weeks after surgery, GFP-positive
cells accumulated in the fibroin grafts (Fig 5, A). GFP-
positive cells that were also positive for -SMA and SM1
were readily detected (Fig 5,A and B). The total number of
SM1-positive cells in grafts gradually increased from 119.0
19.9/section at 1 month to 166.9  29.5/section at 3
months (Fig 5, C). A significant percentage of SM1-
positive cells expressed GFP (65.9%  4.3% at 1 month;
50.9%  4.9% at 3 months; Fig 5, C). These data suggest
that BM-derived cells substantially contribute to the
formation of the SMC layer in the graft in the early
phase. On the other hand, a few BM-derived cells were
positive for CD31 in the luminal layer. Few CD45-
positive cells were observed in the smooth muscle layer
or on the luminal side.
DISCUSSION
In this study, we evaluated the potential of fibroin to
generate a vascular prosthesis for small arteries. A smallartificial vessel with three layers was woven from fibroin
thread. Fibroin-based grafts were implanted into the ab-
dominal aorta of rats by end-to-end anastomosis. The
Fig 3. A, Kaplan-Meier analysis shows graft patency for 27 fi-
broin and 10 polytetrafluoroethylene (PTFE) grafts implanted
into rat aortas at 2, 4, 8, 12, 24, 48, and 72 weeks (see text for
details). B,Histologic analysis of fibroin grafts. Left,Cross section
of the fibroin graft at 4 weeks after implantation (hematoxylin and
eosin staining; scale bar, 100 m). Cells migrated to the fibroin
grafts and covered the luminal side completely. F, Fibroin graft.
L, lumen. Right, The arrowheads indicate media-like layer and
endothelium-like layer, and the arrows indicate fibroin fibers (scale
bar, 50 m). C, Histological analysis of PTFE (P) grafts. Left,
Cross section of the PTFE graft at 4 weeks after implantation
(hematoxylin and eosin staining staining; scale bar, 100 m). L,
Lumen. Right, Very few cells attached on the luminal side of
PTFE graft (scale bar, 50 m). Bottom, Thrombus formation in
the occluded PTFE graft (scale bar, 250 m).patency rate of fibroin grafts at 1 year after implantation was
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cells and SMCs migrated into the fibroin graft early after
implantation and became organized into an endothelium
and a media-like smooth muscle layer. BM-derived cells
substantially contributed to organization of the smooth
muscle layer, but not to endothelium formation.
There is an increasing need for vascular grafts in the field
of surgical revascularization. However, smaller vascular grafts
made from synthetic biomaterials, particularly those 5 mm
in diameter, are associated with a high incidence of thrombo-
sis. Fibroin is a biodegradable protein derived from silk that
provides an antithrombotic surface and serves as an ideal
scaffold for various cell types in tissue engineering.17
Cell attachment, migration, proliferation, and differen-
tiation on biomaterials are critical elements for successful
tissue regeneration.24 In the present study, BMCs were
shown to attach, spread, and proliferate on the silk fiber
matrix. When a fibroin graft was implanted in the rat
abdominal aorta, endothelial cells and SMCs were orga-
nized into a vessel-like structure. The luminal surface of the
Fig 4. A, Macroscopic image of implanted fibroin gra
indicate anastomotic sites. The fibroin grafts appeared to
of thrombosis, stenosis, or mechanical failure. Ao, Aorta
graft at 1 year showed a confluent endothelial layer and
against CD31 and -smooth muscle actin (-SMA), r
macrophage infiltration in the adventitia. Formation of va
and lower panels).graft was almost completely covered by a layer of endothe-lial cells by 12 weeks. Scanning electron microscopy docu-
mented the endothelial integrity of the luminal surface of
the fibroin grafts. Immunohistochemical examination also
showed newly organized endothelium of the fibroin grafts.
It is well known that endothelialization yields antithrom-
bogenic properties.25,26
Most of the fibroin grafts were free of thrombus forma-
tion during the study’s observation period. SMCs accumu-
lated and formed a media-like structure. In addition, we
found that vasa vasorum-like capillaries developed around
the fibroin grafts, suggesting that the newly developed
vessel-like structure can receive a physiologic blood supply
for the maintenance of vascular homeostasis.
It is critical that the material for a vascular conduit can
be sutured and has sufficient burst strength to withstand
physiologic blood pressure. Biodegradable scaffolds to es-
tablish tissue-engineered vascular autografts have been
used for lower-pressure circulation, but not for the arterial
system.27 Recently, we and others reported that fibroin
fiber can produce strong and tough fibers.10,15,28,29 The
) at 1 year shows no aneurysm formation. The arrows
egrated into the surrounding tissue and showed no signs
, inferior vena cava. B, Histologic analysis of the fibroin
th muscle cell layers, as determined by immunostaining
tively. Immunostaining for CD68 revealed substantial
orumwas noted (arrowheads). Scale bar, 100m (upperft (G
be int
; IVC
smoo
espec
sa vasstress-strain curve revealed that the Young’s modulus of the
-pos
or bar
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remarkable combination of strength and toughness.29 We
found that ultimate tensile strength of the fibroin fiber was
Fig 5. A, At 4 to 16 weeks after BMT from GFP rats
chimeric rats. Fibroin grafts transplanted in BMT rats we
with Hoechst 33258 (blue). We readily detected GFP-po
There were few GFP and CD31 (red) double-positive c
newly formed vessel wall-like structure. Scale bar, 100m
cells on fibroin graft at 12 weeks after implantation into
SM1 (red). The arrows indicate double-positive cells. Sca
of the media-like layer. The lower right panel shows a di
(blue). Scale bar, 10 m. C, Frequency of GFP- and SM1
measured at 1 and 3 months after implantation. The err320 MPa and that strain at break was 20%.29Consistently, neither rupture nor aneurysm formation
was observed when a small-diameter vascular graft made
from fibroin was implanted into rat abdominal aorta in the
ild-type SD rats, fibroin grafts were implanted into the
ap-frozen at 4 or 12 weeks. Nuclei were counterstained
cells (green) that were positive for -SMA or SM1 (red).
ew CD45-positive cells (red) were observed within the
epresentative images of BM-derived smoothmuscle-like
rat. Frozen sections were stained for GFP (green) and
r, 20 m. Lower panels are higher magnification images
tial interference contrast microscopic image with nuclei
itive cells in the media-like structure of fibroin grafts was
s indicate the standard error of the mean.to w
re sn
sitive
ells. F
.B,R
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le ba
fferenpresent study. Histologic analysis demonstrated that the
JOURNAL OF VASCULAR SURGERY
Volume 51, Number 1 Enomoto et al 163diameter of the fibroin grafts remained unchanged for up to
18 months. Sirius red staining showed that collagen fibers
were deposited within the fibroin graft along with smooth
muscle accumulation. Sufficient collagen accumulation can
act as a framework and strengthen the graft against high
systemic pressure while the fibroin grafts are gradually
absorbed. It is critical for biodegradable materials to main-
tain sufficient strength until the newly formed organ be-
comes mechanically and physiologically mature. If degra-
dation is too fast before the vessel is organized, rupture or
aneurysm formation potentially occurs. Gradual proteolytic
degradation takes longer in silk11-14: silk fibers generally
lose most of their tensile strength 1 year in vivo and
become unrecognized at the site 2 years.
An adequate inflammatory response seems to be re-
quired for the degradation of silk. Systematic in vivo studies
indicate that silk induces a foreign body response compa-
rable to that of most commonly used degradable synthetic
and natural polymers, such as polyglycolic acid-poly
lactic acid copolymers and collagen.15,30 Similarly, we ob-
served that the content of fibroin was significantly de-
creased at 1 year after implantation. In abdominal wound
closure in rats, silk promoted a moderate foreign body
response compared with monofilament and multifilament
nylon and polyglycolic acid sutures.31 In our study, macro-
phages accumulated around the fibroin grafts at 1 year after
implantation. Few inflammatory cells infiltrated within the
newly formed vessel wall.
We and others previously reported that BM can give
rise to vascular cells that participate not only in repair
but also in lesion formation after injury of the vessel
wall.20,22,32 On the other hand, other authors reported
that BMCs do not participate substantially in vascular
remodeling in some experimental systems.33,34 These
BM-derived vascular cells are considered to be endothelial-
like progenitor cells or smooth muscle-like progenitor
cells.35,36 In the present study, a significant number of
SMCs were observed in the media-like structure derived
from BMCs in the implanted fibroin graft. Some BM-
derived cells expressed not only -SMA but also SM1, a
marker for highly differentiated SMC.
We previously reported that the contribution of BMCs
to arterial remodeling in mice depends on the type of
vascular injury.22,23 BMCs would substantially contribute
to lesion formation when arteries are subjected to severe
injury that kills most endothelial and medial cells. We
speculate that BM-derived cells were recruited to repair
the implanted vascular prosthesis because not enough
local mesenchymal cells were available for the process.
After graft implantation, smooth muscle-like progenitor
cells were recruited and accumulated along the graft. It is
likely that endothelial cells migrated from the adjacent endog-
enous vessel wall.
In this study, we used rat abdominal model to implant
fibroin graft. There are several differences in vascular biol-
ogy and coagulation activity between rodents and humans.
Apparently, there are many limitations to extrapolate data
in this study to clinical use of the vascular prosthesis.37Clinical feasibility of the graft should be evaluated carefully
with preclinical studies using other models with vascular
biology more similar to that of man.38
CONCLUSIONS
Our findings suggest that silk-based fibroin grafts pro-
vide excellent patency when implanted in smaller vessels.
The fibroin graft gradually degraded with formation of an
artery-like structure by endogenous endothelial cells and
SMCs. Fibroin may hold the promise to generate vascular
prostheses for smaller-diameter arteries.
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